CAD technology useful for difficult-to-detect breast cancers
Study findings revealed that CAD technology effectively identified 98 percent of the microcalcifications, 95 percent of the invasive lobular carcinomas, 89 percent of the mixed mass/microcalcification lesions and 84 percent of the masses in 273 women with confirmed breast cancer. The study from the Department of Radiology at The George Washington University Medical Center, concluded that CAD - with an overall sensitivity of 89 percent - represents a useful tool for the detection of breast cancer.
iCAD Inc.'s CAD solutions, specifically its Second Look CAD system, was used in the study, published today in the American Cancer Society's journal Cancer.
Rachel F. Brem, MD, director of Breast Imaging at The George Washington University Medical Center and study principle investigator said, "This study further demonstrates the potential of CAD for the improved diagnosis of breast cancer. It is particularly exciting as it demonstrates the effectiveness of CAD in cancers that are often difficult to detect mammographically such as invasive lobular carcinomas."
The study was conducted over a four-year span from three institutions collecting 1,000 consecutive screen-detected, biopsy-proven breast carcinomas. Every third tumor was selected until 275 consecutive carcinoma tumors were identified at random for system testing. From a consecutive series of 494 women with normal screenings, 155 mammograms were randomly selected for this study.
iCAD Inc.'s CAD solutions, specifically its Second Look CAD system, was used in the study, published today in the American Cancer Society's journal Cancer.
Rachel F. Brem, MD, director of Breast Imaging at The George Washington University Medical Center and study principle investigator said, "This study further demonstrates the potential of CAD for the improved diagnosis of breast cancer. It is particularly exciting as it demonstrates the effectiveness of CAD in cancers that are often difficult to detect mammographically such as invasive lobular carcinomas."
The study was conducted over a four-year span from three institutions collecting 1,000 consecutive screen-detected, biopsy-proven breast carcinomas. Every third tumor was selected until 275 consecutive carcinoma tumors were identified at random for system testing. From a consecutive series of 494 women with normal screenings, 155 mammograms were randomly selected for this study.